Equites Radar

QGEN · Qiagen N.V.

Diagnostics & ResearchNetherlandsAnalyst view: Buy

$41.37

+2.92% last session

End-of-day data · updated 2026-07-28

Mildly bearish1 bullish · 3 bearish technical signals
Consensus: Buy (2.13 from 14 analysts)
To mean target: +6.5%

Market cap

$8B

Enterprise value

$9B

Trailing P/E

21.0

Forward P/E

15.7

Dividend yield

1.0%

Beta

0.64

Avg volume

3M

Employees

6K

2D change

-0.70%

5D change

-0.89%

10D change

-0.17%

30D change

5.18%

60D change

13.28%

MTD change

5.93%

YTD change

-7.83%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.13
Covering analysts14
Mean price target$44.07
Low price target$36.00
Upside to mean target+6.5%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)65.4
50-day MA$37.80
200-day MA$42.88
Price vs 50-day MA+11.9%
Price vs 200-day MA-1.4%
MACD histogram-0.03
Volume vs 3-month avg0.7×
52w low $32.3452w high $55.16

Analyst sentiment over time — QGEN

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-06-23

Latest call per bank · past 12 months

Morgan Stanley

Overweight

$42.00

+1.5% vs price
▲ raised from $40.00Upgrade · 2026-06-23

JP Morgan

Overweight

$45.00

+8.8% vs price
▼ cut from $60.00Maintains · 2026-04-29

Citigroup

Neutral

$38.00

-8.1% vs price
▼ cut from $55.00Maintains · 2026-04-29

Barclays

Equal-Weight

$38.00

-8.1% vs price
▼ cut from $44.00Maintains · 2026-04-29

Deutsche Bank

Buy

$54.00

+30.5% vs price
Upgrade · 2026-03-13

UBS

Neutral

$50.00

+20.9% vs price
▲ raised from $48.00Maintains · 2025-08-07

Recent rating actions

DateFirmActionRatingPrice target
2026-06-23Morgan StanleyUpgradeEqual-WeightOverweight$40.00 $42.00
2026-05-18StifelMaintainsHold$50.00 $36.00
2026-05-07TD CowenMaintainsHold$46.00 $40.00
2026-04-29JP MorganMaintainsOverweight$60.00 $45.00
2026-04-29CitigroupMaintainsNeutral$55.00 $38.00
2026-04-29BarclaysMaintainsEqual-Weight$44.00 $38.00
2026-04-29BairdUpgradeNeutralOutperform$53.00 $43.00
2026-04-14BarclaysDowngradeOverweightEqual-Weight$0.00 $44.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 65 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 11.8% above the 50-day MA ($37.80).
  • Price vs 200-day MA: Trading 1.4% below the 200-day MA ($42.88).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($32.34) and high ($55.16).

QGEN Price Chart

Loading chart for QGEN

Fundamentals

Revenue (TTM)$2.0B
EBITDA$1.0B
Free cash flow$0M
Operating cash flow$1.0B
Book value / share$16.15
Net debt / EBITDA1.4
WACC8.0%
Revenue growth2.00%
Earnings growth-24.00%

About Qiagen N.V.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

More in Diagnostics & Research

Screen QGEN against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.